Cargando…

Lung adenocarcinoma with an uncommon CCDC85A‐ALK fusion responding to alectinib: A case report

A 55‐year‐old Chinese man with a right lung mass and lymph node metastasis (T4N3M0 IIIB) was diagnosed with lung adenocarcinoma after a CT‐guided biopsy. With the wide application of next‐generation sequencing (NGS) in tumour detection, we found a rare CCDC85A‐ALK fusion. The patient received alecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Jieheng, Wang, Wenping, Lin, Jietao, Chen, Ruilian, Cao, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575090/ https://www.ncbi.nlm.nih.gov/pubmed/36102237 http://dx.doi.org/10.1111/jcmm.17520

Ejemplares similares

ALK ‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
por: Song, Lianxi, et al.
Publicado: (2022)

Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib
por: Guo, Weihong, et al.
Publicado: (2022)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

A Novel LINC00478/LINC01549 Intergenic Region-ALK Fusion Responded Well to Alectinib in a Patient With Lung Adenocarcinoma
por: Peng, Wei, et al.
Publicado: (2020)

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib
por: Sunga, Cass G. G., et al.
Publicado: (2023)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report
por: Yan, Lingxin, et al.
Publicado: (2023)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
por: Zeng, Hao, et al.
Publicado: (2021)

Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report
por: Ning, Shangkun, et al.
Publicado: (2021)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
por: Su, Cuiyun, et al.
Publicado: (2020)

Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
por: Gu, Xiaodong, et al.
Publicado: (2022)

Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant
por: Song, Peng, et al.
Publicado: (2018)

ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare ALK fusion sites: a case report
por: Li, Yan, et al.
Publicado: (2022)

Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1‐ALK fusion
por: Yin, Qiang, et al.
Publicado: (2021)

A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
por: Deng, Ling, et al.
Publicado: (2022)

A novel intergenic region (chr2: 30,193,816)-ALK fusion shows sensitivity to Alectinib in lung adenocarcinoma
por: Wang, Ting, et al.
Publicado: (2023)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2023)

Mixed responses to first‐line alectinib in non‐small cell lung cancer patients with rare ALK gene fusions: A case series and literature review
por: Li, Mengnan, et al.
Publicado: (2021)

Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report
por: Zhu, Lin, et al.
Publicado: (2023)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report
por: Wang, Hongbiao, et al.
Publicado: (2022)

Partial treatment response to alectinib in metastatic non-small cell lung cancer with KIDINS220-ALK fusion
por: Lei, Yanna, et al.
Publicado: (2023)

ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and Ceritinib
por: Kaiho, Taisuke, et al.
Publicado: (2020)

Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature
por: Hsiao, Sheng-Yen, et al.
Publicado: (2021)

Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib
por: Xue, Feng, et al.
Publicado: (2022)

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review
por: Isaka, Yuri, et al.
Publicado: (2023)

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report
por: Zhang, Linlin, et al.
Publicado: (2022)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib
por: Lim, Chloe A., et al.
Publicado: (2022)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vi6iqgp3t5v56ebujaq17ghfa0